TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

About this episode

Experts discuss the integration of TROP2-directed antibody-drug conjugates in managing advanced NSCLC, focusing on efficacy, safety, and future directions.

In this episode, experts discuss the available efficacy and safety evidence along with their experiences with and strategies for integrating TROP2-directed antibody-drug conjugates into the management of patients with advanced NSCLC, with an emphasis on EGFR-mutant disease and a look at future therapeutic directions on the horizon.

Topics covered

• TROP2-directed therapy
• non-small-cell lung cancer
• EGFR mutations
• clinical practice
• future therapeutic directions

Keywords

• TROP2
• antibody-drug conjugates
• NSCLC
• EGFR-mutant
• clinical practice
• therapeutic directions

Mentioned in this episode

Organizations: TROP2-directed antibody-drug conjugates, NSCLC, EGFR

More episodes of Decera Clinical Education Oncology Podcast

• Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness · June 9, 2026 · 27 min
• HNSCC: Current and Emerging Therapeutic Strategies · May 29, 2026 · 26 min
• Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies · May 15, 2026 · 21 min
• Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma · May 7, 2026 · 31 min
• Thrombotic Events and ET/PV: What You Should Know · April 30, 2026 · 22 min
• Global Experts Discuss Current and Emerging Treatments for ET and PV · April 30, 2026 · 17 min